Skip Navigation


JAC Advance Access originally published online on January 16, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
53/2/311    most recent
dkh055v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Takemoto, K.
Right arrow Articles by Niki, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takemoto, K.
Right arrow Articles by Niki, Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2004) 53, 311-317
© 2004 The British Society for Antimicrobial Chemotherapy

Comparative studies on the efficacy of AmBisome and Fungizone in a mouse model of disseminated aspergillosis

Koji Takemoto1,*, Yutaka Yamamoto1, Yutaka Ueda1, Yoshihiro Sumita1, Koichiro Yoshida2 and Yoshihito Niki2

1 Sumitomo Pharmaceuticals Research Division, 1–98, Kasugadenaka 3-chome, Konohana-ku, Osaka 554–0022; 2 Division of Respiratory Disease, Department of Medicine, Kawasaki Medical School, 577, Matsushima, Kurashiki 701–0192, Japan

Received 17 July 2003; returned 13 September 2003; revised 19 October 2003; accepted 5 November 2003

Objectives: The efficacy of intravenous injections of a liposomal formulation of amphotericin B (AmBisome) and amphotericin B deoxycholate (Fungizone) was evaluated in immunocompetent and temporarily leucopenic mouse models of disseminated aspergillosis using seven isolates of Aspergillus.

Methods: Mice were infected with the organisms via tail veins. At 4 h after infection, antifungals were administered intravenously. For 30 days the number of mice surviving was recorded.

Results: AmBisome at 1 mg/kg or higher significantly prolonged the survival time of mice infected with five out of seven isolates of Aspergillus compared with the control group. There was no difference in in vivo activity between AmBisome and Fungizone at 1 mg/kg in six isolates of Aspergillus. At the maximum tolerated dose of antifungals, however, AmBisome (10 mg/kg) showed greater efficacy than Fungizone (1 mg/kg).

Conclusions: These results suggest that the overall protective activity of AmBisome against disseminated aspergillosis is superior to that of Fungizone.

Keywords: liposomal amphotericin B, amphotericin B deoxycholate, Aspergillus, tolerability

* Corresponding author. Tel: +81-6-6466-5271; Fax: +81-6-6466-5491; E-mail: ktakemot{at}sumitomopharm.co.jp


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
K. Takemoto, Y. Yamamoto, Y. Ueda, Y. Sumita, K. Yoshida, and Y. Niki
Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis
J. Antimicrob. Chemother., April 1, 2006; 57(4): 724 - 731.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.